Market Place
Sourcing Support
Vertex Presents CF Data At North American Conference
26 Sep 2024 //
BUSINESSWIRE
Vertex inks long-term access deal for CF meds in Englan
22 Jun 2024 //
FIERCE PHARMA
Vertex`s sales of Trikafta hit $8.9B thanks to label expansion
06 Feb 2024 //
FIERCE PHARMA
Vertex meets own cystic fibrosis record with next-gen treatment
06 Feb 2024 //
FIERCE BIOTECH
Vertex Announces EMA Validation for MAA Extension for KAFTRIO
24 Nov 2023 //
BUSINESSWIRE
EC Approves KAFTRIO® in Combination With Ivacaftor
23 Nov 2023 //
BUSINESSWIRE
NICE rejects cost effectiveness of Vertex`s cystic fibrosis meds
07 Nov 2023 //
FIERCE PHARMA
Vertex Receives CHMP Positive Opinion for KAFTRIO
15 Sep 2023 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA in Children With Cystic Fibrosis
27 Apr 2023 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA in Children With CF
26 Apr 2023 //
BUSINESSWIRE
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA
26 Mar 2022 //
BUSINESSWIRE
Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance
17 Sep 2021 //
BIOSPACE
Vertex Announces Publication in The New England Journal of Medicine
26 Aug 2021 //
BUSINESSWIRE
Vertex Announces National Reimbursement Agreement in France for KAFTRIO
28 Jun 2021 //
BUSINESSWIRE
Health Canada Grants Marketing Authorization for TRIKAFTA
18 Jun 2021 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA
09 Jun 2021 //
BUSINESSWIRE
Vertex Announces European Commission Approval for KAFTRIO®
28 Apr 2021 //
BUSINESSWIRE
Symkevi/Kalydeco cleared for use in young CF patients
01 Dec 2020 //
PHARMATIMES
Vertex Announces European Commission Approval for SYMKEVI®
26 Nov 2020 //
BUSINESSWIRE
EMA recommends eight new medicines, refuses one
27 Jun 2020 //
RAPS
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
27 Nov 2019 //
RAPS
‘Impressive’ results for Trikafta in cystic fibrosis
02 Nov 2019 //
PHARMATIMES
Phase 3 Results from Two Studies of TRIKAFTA
31 Oct 2019 //
BUSINESSWIRE
Vertex inks agreement with NHS England for access to all licensed CF medicines
30 Oct 2019 //
BUSINESSWIRE
Trikafta wins FDA approval for CF (Approval)
22 Oct 2019 //
PHARMATIMES
Spanish Government Approves National Reimbursement of ORKAMBI®
21 Oct 2019 //
BUSINESSWIRE
Vertex deal for Scotland — no deal for England
13 Sep 2019 //
ENDPTS
Vertex sinks on reports of deaths of patients taking cystic fibrosis drug
28 Aug 2019 //
STATNEWS
FDA Grants Priority Review to Vertex’s 1st Triple Combo for CF
27 Aug 2019 //
CYSTICFIBROSISNEWS TODAY
FDA Accepts New Drug Application for VX-445 (Elexacaftor) Tezacaftor & Ivacaftor
20 Aug 2019 //
BUSINESSWIRE
Vertex faces rejection of its CF medicines in Scotland
14 Aug 2019 //
PMLIVE
As negotiations with England labor on, Scotland rejects Vertex`s drugs
13 Aug 2019 //
ENDPTS
Vertex touts Symdeko success after CEO turnover, Orkambi stumble
31 Jul 2019 //
FIERCE PHARMA
FDA expands approval of treatment for cystic fibrosis
21 Jun 2019 //
PR NEWSWIRE
The top 10 blockbuster drugs in the late-stage pipeline
19 Jun 2019 //
ENDPTS
Vertex makes choice for all-important CF triple therapy
01 Jun 2019 //
PMLIVE
Finding a winner in VX-445, Vertex hustles CF combo to regulators on both sides
31 May 2019 //
ENDPTS
Epizyme moves forward with cancer drug, eyes 2020 launch
30 May 2019 //
BIOPHARMADIVE
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
01 Feb 2019 //
PM LIVE
Vertex`s Triple-Combo CF Drugs Dazzle in Data from 2 Phase III Trials
27 Nov 2018 //
BIOSPACE
Vertex Pharma`s Symkevi (tezacaftor,ivacaftor) Receives Approval in Europe
27 Nov 2018 //
EMA
Vertex CEO- competitive edge is honed and ready for AbbVie`s CF grab
26 Oct 2018 //
FIERCE PHARMA
Vertex Completes Enrollment of 2 PhIII Studies on VX-659+Tezacaftor+ Ivacaftor
06 Sep 2018 //
BUSINESSWIRE
Vertex Finalizes Orkambi Deal With Australia
04 Sep 2018 //
BIOCENTURY
Meeting highlights from the CHMP 23-26 July 2018
31 Jul 2018 //
EMA
Vertex and Alnylam orphan drugs set for EU approval
30 Jul 2018 //
PHARMAPHORUM
Patients wait as Vertex, U.K. officials argue over Orkambi price
09 Jul 2018 //
FIERCE PHARMA
Health Canada Approves PrSYMDEKO™ tezacaftor/ivacaftor Cystic Fibrosis
29 Jun 2018 //
BUSINESSWIRE
Worldwide drug forecasts rise again, but clouds remain
06 Jun 2018 //
EPVANTAGE
FDA has dosing questions for Vertex’s Kalydeco follow-up
28 Apr 2018 //
ENDPTS
